Swertisin

Swertisin is an oral adenosine A1 receptor antagonist and an SGLT2 inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice[1][2][3].

Product Specifications

CAS Number

[6991-10-2]

UNSPSC

12352005

Target

Adenosine Receptor; HBV; SGLT

Type

Natural Products

Related Pathways

Anti-infection; GPCR/G Protein; Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Infection; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/swertisin.html

Purity

99.54

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1C=C(C2=CC=C(O)C=C2)OC3=CC(OC)=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=C13

Molecular Formula

C22H22O10

Molecular Weight

446.40

References & Citations

[1]Oh HK, et al. Swertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in mice. J Psychopharmacol. 2017 Feb;31 (2) :250-259.|[2]Gurprit Bhardwaj, et al. Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy. Arch Biochem Biophys. 2021 Oct 15:710:108995.|[3]Hong-Yan Xu, et al. Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum Maxim. J Ethnopharmacol. 2020 Jul 15:257:112787.